2020 Could Spell The End Of Mega-Mergers, For Now
Instead Expect A Wave Of Mid-Sized Deals In 2020, Industry Watchers Say
Executive Summary
Industry experts expect a continued uptick in deals valued between $2bn-$10bn this year as buyers look to add critical mass in areas like oncology, rare disease and cell and gene therapy. Divestitures to free up capital and narrow focus should continue too.
You may also be interested in...
Biopharma Deal Value, Volume Tumbled Substantially During First Half
A PwC analysis finds biopharma aggregate deal value declined 87% during the first half compared to the second half of 2018; deal volume dropped 17%. The pandemic was a cause, but not the only factor.
BIO 2020 Notebook: Conversations On Rebates, Racism And Remote Working
News and views from day four of BIO Digital also include discussion of whether the pandemic is discouraging mega mergers.
BIO 2020 Notebook: Conversations On Rebates, Racism, And Remote Working
News and views from day four of BIO Digital also include discussion of whether the pandemic is discouraging mega mergers.